MD3927F1 - Method for treating the facial paralysis - Google Patents
Method for treating the facial paralysisInfo
- Publication number
- MD3927F1 MD3927F1 MDA20080102A MD20080102A MD3927F1 MD 3927 F1 MD3927 F1 MD 3927F1 MD A20080102 A MDA20080102 A MD A20080102A MD 20080102 A MD20080102 A MD 20080102A MD 3927 F1 MD3927 F1 MD 3927F1
- Authority
- MD
- Moldova
- Prior art keywords
- days
- daily
- compositum
- over
- administered
- Prior art date
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Inventia se refera la medicina, neurologie, pediatrie si este destinata tratamentului paraliziei faciale la nou-nascuti, sugari, copii si maturi. Metoda, conform inventiei, consta in aceea ca se administreaza per os preparatele Bryaconeel si Engystol N cate 1/4…1 pastila, Lymphomyosot si Galium-Heel cate 3…10 picaturi timp de 1 luna de 3 ori pe zi si subcutanat preparatele Traumeel S cate 0,3…2,2 ml zilnic in primele 3 zile, apoi peste 1 zi, Cerebrum compositum N cate 0,3…2,2 ml zilnic in primele 2 zile, apoi peste 2 zile, Gelsemium-Homaccord cate 0,3…1,1 ml zilnic in primele 3 zile, apoi peste 2 zile, Aconitum-Homaccord cate 0,3…1,1 ml zilnic in primele 3 zile, apoi peste 2 zile, Echinacea compositum S cate 0,3…2,2 ml de 2 ori pe saptamana, la o serie de tratament de 7…10 injectii, precum si Coenzyme compositum si Ubichinon compositum cate 0,3…2,2 ml o data pe saptamana, la o serie de tratament de 2…4 injectii. Totodata, preparatele mentionate se administreaza in urmatoarele puncte biologic active: E1,2,3,4,6,7,8,36,44; V1,2,3, 10,11,60; VB1,3,14,20,21,34,39; TR23; IG18; GI19,20; T 14, 26,27; G14,10,11; AP11,14,33,35,37; J24; P7; RP6. In fiecare punct biologic activ se introduce un singur preparat medicamentos, care se administreaza cate 0,1…0,4 ml in 3…5 puncte, totodata in fiecare zi se selecteaza diferite puncte biologic active. Revendicari: 1The invention relates to medicine, neurology, pediatrics and is intended for the treatment of facial paralysis in newborns, infants, children and adults. The method, according to the invention, consists in that Bryaconeel and Engystol N preparations are administered by bone 1/4 ... 1 pill, Lymphomyosot and Galium-Heel each 3 ... 10 drops for 1 month 3 times daily and subcutaneously Traumeel S preparations each 0.3 ... 2.2 ml daily for the first 3 days, then over 1 day, Cerebrum compositum N each 0.3 ... 2.2 ml daily for the first 2 days, then over 2 days, Gelsemium-Homaccord 0.3 … 1.1 ml daily in the first 3 days, then over 2 days, Aconitum-Homaccord each 0.3… 1.1 ml daily within the first 3 days, then over 2 days, Echinacea compositum S each 0.3… 2.2 ml twice a week, for a series of 7 ... 10 injections, as well as Coenzyme compositum and Ubichinon compositum each 0.3 ... 2.2 ml once a week, for a series of 2 ... 4 injections. At the same time, the mentioned preparations are administered in the following biologically active points: E1,2,3,4,6,7,8,36,44; V1,2,3, 10,11,60; VB1,3,14,20,21,34,39; TR23; IG18; GI19,20; T 14, 26.27; G14,10,11; AP11,14,33,35,37; J24; P7; RP6. In each biologically active point, a single drug preparation is introduced, which is administered 0.1 to 0.4 ml in 3 ... 5 points, while each biologically active point is selected. Claimant: 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDA20080102A MD3927G2 (en) | 2008-04-07 | 2008-04-07 | Method for treating the facial paralysis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDA20080102A MD3927G2 (en) | 2008-04-07 | 2008-04-07 | Method for treating the facial paralysis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MD3927F1 true MD3927F1 (en) | 2009-06-30 |
| MD3927G2 MD3927G2 (en) | 2010-01-31 |
Family
ID=40942304
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDA20080102A MD3927G2 (en) | 2008-04-07 | 2008-04-07 | Method for treating the facial paralysis |
Country Status (1)
| Country | Link |
|---|---|
| MD (1) | MD3927G2 (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1483373A1 (en) * | 1986-10-17 | 1989-05-30 | Всесоюзный научно-исследовательский центр по охране здоровь матери и ребенка | Method for forecasting disorders of cerebral blood circulation of newborn infants |
| RU2164082C1 (en) * | 2000-03-07 | 2001-03-20 | Новокузнецкий государственный институт усовершенствования врачей | Method for diagnosing the central nervous system stage of a fetus |
| UA78490C2 (en) * | 2002-11-12 | 2007-04-10 | Univ Odesa State Medical | Method for predicting and treating facial paralysis |
-
2008
- 2008-04-07 MD MDA20080102A patent/MD3927G2/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| MD3927G2 (en) | 2010-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201101518A1 (en) | PHARMACEUTICAL COMPOSITION FOR USE IN MEDICAL AND VETERINARY OPHTHALMOLOGY | |
| EA201591529A1 (en) | TREATMENT OF CHILDREN'S DEFICIENCY OF GROWTH HORMONE BY HUMAN ANALOGUES OF HORMONE GROWTH | |
| RS54561B1 (en) | Composition for controlled ovarian stimulation | |
| Mercuri et al. | SUNFISH part 2: efficacy and safety of risdiplam (RG7916) in patients with Type 2 or non-ambulant Type 3 spinal muscular atrophy (SMA) | |
| UY31418A1 (en) | USE OF THERAPEUTIC HUMAN ALBUMIN FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF PATIENTS AFFECTED BY COGNITIVE DISORDERS | |
| Bobes-García et al. | Delphi consensus on the physical health of patients with schizophrenia: evaluation of the recommendations of the spanish societies of psychiatry and biological psychiatry by a panel of experts | |
| MD3359F1 (en) | Method of conservative treatment of diskal hernia | |
| Kutlar et al. | Pomalidomide in sickle cell disease: phase I study of a novel anti-switching agent | |
| MD3927F1 (en) | Method for treating the facial paralysis | |
| MD3803F1 (en) | Method of treating hyperkinesia of children | |
| Patel et al. | An open-label, randomized, multicenter, controlled study of epoetin alfa for the treatment of anemia of chronic kidney disease in the long term care setting | |
| MD3906F1 (en) | Method for treating the neurotic enuresis to children | |
| MD3940F1 (en) | Method for treating the brachial paralysis | |
| BR112017022478A2 (en) | pharmaceutical sustained release composition containing rivastigmine | |
| Castrillón JL et al. | COVID-19 and vitamin D. Position paper of the Spanish Society for Bone Research and Mineral Metabolism (SEIOMM). | |
| Bagel et al. | Secukinumab is Superior to Ustekinumab in Clearing Skin of Patients with Moderate to Severe Plaque Psoriasis: CLARITY, a Randomized, Controlled, Phase 3b Trial | |
| Rosencher et al. | Real-world study of dabigatran etexilate for thromboprophylaxis in over 5000 hip or knee replacement patients: favourable safety profile in subgroups with different BMI, renal function and age | |
| Zhou et al. | Traditional Chinese medicine. | |
| MD3885F1 (en) | Method for polyparasitosis complex treatment to cattle | |
| BR112022006748A2 (en) | METHODS FOR TREATMENT OF AN INDIVIDUAL SUFFERING FROM WEIGHT GAIN AND AT RISK OF ANTIPSYCHOTIC-INDUCED WEIGHT GAIN | |
| Andorn et al. | Monthly extended-release risperidone (RBP-7000) in the treatment of schizophrenia | |
| MD3361F1 (en) | Method of treating the infantile cerebral paralysis | |
| Golpayegani et al. | The Comparison of Desfonak with Desferal in Patients with Beta Thalassemia Major: A Randomized Crossover Clinical Trial | |
| TR202100205U5 (en) | PILL-MATIC | |
| Paula | Vitamin D: more does not mean better |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG4A | Patent for invention issued | ||
| KA4A | Patent for invention lapsed due to non-payment of fees (with right of restoration) | ||
| MM4A | Patent for invention definitely lapsed due to non-payment of fees |